Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages

Infection and Immunity

Volumn 67, Issue 9, 1999, Pages 4485-4489

  Ding, Aihao ^a   Thieblemont, Nathalie ^b   Zhu, Jing ^a   Jin, Fenyu ^c   Zhang, Jenny ^a   Wright, Samuel ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD18 ANTIGEN; LEUKOCYTE PROTEASE INHIBITOR; LIPOPOLYSACCHARIDE; PROTEINASE INHIBITOR; RECOMBINANT SECRETORY LEUKOCYTE PROTEASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CARBOHYDRATE TRANSPORT; COMPLEX FORMATION; CONTROLLED STUDY; GENE OVEREXPRESSION; INHIBITION KINETICS; MACROPHAGE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEINASE INHIBITION;

EID: 0032773727     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.9.4485-4489.1999     Document Type: Article

References (42)

1. Blasi, E., D. Radzioch, S. K. Durum, and L. Varesio. 1987. A murine macrophage cell line, immortalized by v-raf and v-myc oncogenes, exhibits normal macrophage functions. Eur. J. Immunol. 17:1491-1498.
2. Bohm, B., T. Aigner, R. Kinne, and H. Burkhardt. 1992. The serine-protease inhibitor of cartilage matrix is not a chondrocytic gene product. Eur. J. Biochem. 207:773-779.
3. Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457-469.
4. Cox, G. W., B. J. Mathieson, L. Gandino, E. Blasi, D. Radzioch, and L. Varesio. 1989. Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver. J. Natl. Cancer Inst. 81:1492-1496.
5. Detmers, P. A., N. Thieblemont, T. Vasselon, R. Pironkova, D. S. Miller, and S. D. Wright. 1996. Potential role of membrane internalization and vesicle fusion in adhesion of neutrophils in response to lipopolysaccharide and TNF. J. Immunol. 157:5589-5596.
6. Dietze, S. C., C. P. Sommerhoff, and H. Fritz. 1990. Inhibition of histamine release from human mast cells ex vivo by natural and synthetic chymase inhibitors. Biol. Chem. Hoppe-Seyler 371:75-79.
7. Fath, M. A., X. Wu, R. E. Hileman, R. J. Linhardt, M. A. Kashem, R. M. Nelson, C. D. Wright, and W. M. Abraham. 1998. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J. Biol. Chem. 273:13563-13569.
8. Fink, E., R. Nettelbeck, and H. Fritz. 1986. Inhibition of mast cell chymase by eglin c and antileukoprotease (HUSI-I). Indications for potential biological functions of these inhibitors. Biol. Chem. Hoppe-Seyler 367:567-571.
9. Flaherty, S. F., D. T. Golenbock, F. H. Milham, and R. R. Ingalls. 1997. CD11/CD18 leukocyte integrins: new signaling receptors for bacterial endotoxin. J. Surg. Res. 73:85-89.
10. Frey, E. A., D. S. Miller, T. G. Jahr, A. Sundan, V. Bazil, T. Espevik, B. B. Finlay, and S. D. Wright. 1992. Soluble CD14 participates in the response of cells to lipopolysaccharide. J. Exp. Med. 176:1665-1671.
11. Fritz, H. 1988. Human mucus proteinase inhibitor (human MPI). Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI). Biol. Chem. Hoppe-Seyler 369:79-82.
12. Grobmyer, S. R., P. S. Barie, C. F. Nathan, M. Fuortes, E. Lin, S. F. Lowry, C. D. Wright, M. J. Weyant, L. Hydo, F. Reeves, M. U. Shiloh, and A. Ding. Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit. Care Med., in press.
13. Grutter, M. G., G. Fendrich, R. Huber, and W. Bode. 1988. The 2.5 A X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. EMBO J. 7:345-351.
14. Hailman, E., J. J. Albers, G. Wolfbauer, A. Y. Tu, and S. D. Wright. 1996. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J. Biol. Chem. 271:12172-12178.
15. Hailman, E., H. S. Lichenstein, M. M. Wurfel, D. S. Miller, D. A. Johnson, M. Kelley, L. A. Busse, M. M. Zukowski, and S. D. Wright. 1994. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J. Exp. Med. 179:269-277.
16. Hailman, E., T. Vasselon, M. Kelley, L. A. Busse, M. C. Hu, H. S. Lichenstein, P. A. Detmers, and S. D. Wright. 1996. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J. Immunol. 156:4384-4390.
17. Hiemstra, P. S., R. J. Maassen, J. Stolk, R. Heinzel-Wieland, G. J. Steffens, and J. H. Dijkman. 1996. Antibacterial activity of antileukoprotease. Infect. Immun. 64:4520-4524.
18. Ingalis, R. R., and D. T. Golenbock. 1995. CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J. Exp. Med. 181:1473-1479.
19. Jin, F., C. F. Nathan, D. Radzioch, and A. Ding. 1998. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect. Immun. 66: 2447-2452.
20. Jin, F. Y., C. Nathan, and A. Ding. 1999. Paradoxical preservation of an LPS response in C3H/HeJ macrophages: induction of matrix metalloproteinase-9. J. Immunol. 162:3596-3600.
21. Jin, F. Y., C. Nathan, D. Radzioch, and A. Ding. 1997. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88:417-426.
22. Kramps, J. A., C. van Twisk, H. Appelhans, B. Meckelein, T. Nikiforov, and J. H. Dijkman. 1990. Proteinase inhibitory activities of antileukoprotease are represented by its second COOH-terminal domain. Biochim. Biophys. Acta 1038:178-185.
23. Lee, J. D., K. Kato, P. S. Tobias, T. N. Kirkland, and R. J. Ulevitch. 1992. Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein. J. Exp. Med. 175:1697-1705.
24. McNeely, T. B., M. Dealy, D. J. Dripps, J. M. Orenstein, S. P. Eisenberg, and S. M. Wahl. 1995. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Investig. 96:456-464.
25. McNeely, T. B., D. C. Shugars, M. Rosendahl, C. Tucker, S. P. Eisenberg, and S. M. Wahl. 1997. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90:1141-1149.
26. Morrison, D. C., and J. L. Ryan. 1979. Bacterial endotoxins and host immune responses. Adv Immunol. 28:293-450.
27. Nathan, C. F. 1987. Secretory products of macrophages. J. Clin. Investig. 79:319-326.
28. Ohlsson, K., M. Bergenfeldt, and P. Bjork. 1988. Functional studies of human secretory leukocyte protease inhibitor. Adv. Exp. Med. Biol. 240: 123-131.
29. Park, C. T., A. A. Creasey, and S. D. Wright. 1997. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 89:4268-4274.
30. Parker, M. M., and J. E. Parrillo. 1983. Septic shock. Hemodynamics and pathogenesis. JAMA 250:3324-3327.
31. Qureshi, S. T., L. Larivière, G. Leveque, S. Clermont, K. J. Moore, P. Gros, and D. Malo. 1999. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189:611-614.
32. Raetz, C. R., R. J. Ulevitch, S. D. Wright, C. H. Sibley, A. Ding, and C. F. Nathan. 1991. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 5:2652-2660.
33. Sultzer, B. M. 1968. Genetic control of leucocyte responses to endotoxin. Nature 219:1253-1254.
34. Sultzer, B. M. 1969. Genetic factors in leucocyte responses to endotoxin: further studies in mice. J. Immunol. 103:32-38.
35. Thompson, R. C., and K. Ohlsson. 1986. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc. Natl. Acad. Sci. USA 83:6692-6696.
36. Vasselon, T., R. Pironkova, and P. A. Detmers. 1997. Sensitive responses of leukocytes to lipopolysaccharide require a protein distinct from CD14 at the cell surface. J. Immunol. 159:4498-4505.
37. Watson, J., M. Largen, and K. P. McAdam. 1978. Genetic control of endotoxic responses in mice. J. Exp. Med. 147:39-49.
38. Wright, S. D. 1999. Innate recognition of microbial lipids. In R. S. J. I. Gallin, D. Fearon, B. Haynes, and C. Nathan (ed.), Inflammation: basic principles and clinical correlates. Raven Press, New York, N.Y.
39. Wright, S. D., and M. T. Jong. 1986. Adhesion-promoting receptors on human macrophages recognize Escherichia coli by binding to lipopolysaccharide. J. Exp. Med. 164:876-1888.
40. Wright, S. D., R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433.
41. Yu, B., and S. D. Wright. 1996. Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. J. Biol. Chem. 271:4100-4105.
42. Zhang, Y., D. L. DeWitt, T. B. McNeely, S. M. Wahl, and L. M. Wahl. 1997. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2 and matrix metalloproteinases. J. Clin. Investig. 99:894-900.